- Home
- REX vs EYPT Comparison
REX vs EYPT Comparison
Compare REX & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | EYPT |
|---|---|---|
| Founded | 1980 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | REX | EYPT |
|---|---|---|
| Price | $45.12 | $13.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $25.00 | ★ $31.80 |
| AVG Volume (30 Days) | 208.7K | ★ 1.1M |
| Earning Date | 03-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $650,487,000.00 | $7,539,000.00 |
| Revenue This Year | $19.45 | N/A |
| Revenue Next Year | N/A | $1,031.72 |
| P/E Ratio | $18.17 | ★ N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $30.02 | $3.91 |
| 52 Week High | $64.95 | $19.11 |
Technical Indicators
Market Signals| Indicator | REX | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 67.02 | 46.16 |
| Support Level | $31.24 | $12.47 |
| Resistance Level | $55.35 | $14.54 |
| Average True Range (ATR) | 2.25 | 0.72 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 68.39 | 69.30 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.